Amyloid-related imaging abnormalities-edema seen on brain MRI most common adverse event in participants receiving high-dose aducanumab
Concomitant use of central nervous system-depressant drugs listed for 58.4 percent of off-label gabapentin visits
Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid
Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health
Combining varenicline with nicotine patch, extending treatment from 12 to 24 weeks did not increase smoking cessation rates
However, most common product type and intent of use associated with these visits vary by age
Does not improve primary outcome, but did improve performance on certain cognitive tasks in those with epileptiform activity
Overall, 92.2, 91.0, and 85.5 percent of Medicare beneficiaries with ADRDs, Alzheimer disease, and MCI met at least one of the exclusion criteria
0.5-mg and 1-mg tablets may contain levels of N-nitroso-varenicline at or above levels approved by the FDA
Patients with acne prescribed isotretinoin less likely to engage in suicidal behavior than those treated with antibiotics only or those in the general population